Overview
- Medpace reported adjusted EPS of $3.86 and revenue of $659.9 million, with sales up nearly 24% year over year.
- Management raised full-year guidance to $14.60–$14.86 in adjusted EPS and $2.48 billion–$2.53 billion in revenue.
- Net new business awards reached $789.6 million for a 1.20x book-to-bill, up roughly 30% sequentially and about 60% versus the first quarter.
- Backlog rose to approximately $3 billion, with analysts noting recent wins include large metabolic and GLP-1 programs.
- Shares rose roughly 7%–8% after the report as analysts lauded the quarter, calling it a strong beat with notable booking momentum.